Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: The prognostic role of microalbuminuria in TIA evolution (ProMOTE) study by Strain, WD et al.
1Strain WD, et al. BMJ Open 2021;11:e043253. doi:10.1136/bmjopen-2020-043253
Open access 
Evaluation of microalbuminuria as a 
prognostic indicator after a TIA or 
minor stroke in an outpatient setting: 
the prognostic role of microalbuminuria 
in TIA evolution (ProMOTE) study
W David Strain   ,1,2,3 Salim Elyas,1,2 Nicola Wedge,2,3 Luke Mounce   ,4 
William Henley,4 Martin James,2 Angela C Shore1,3
To cite: Strain WD, Elyas S, 
Wedge N, et al.  Evaluation 
of microalbuminuria as a 
prognostic indicator after a TIA 
or minor stroke in an outpatient 
setting: the prognostic role 
of microalbuminuria in 
TIA evolution (ProMOTE) 
study. BMJ Open 
2021;11:e043253. doi:10.1136/
bmjopen-2020-043253
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online. 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2020- 043253).
Received 14 September 2020
Accepted 25 June 2021
1Diabetes and Vascular 
Research Centre, University of 
Exeter, Exeter, UK
2Academic Department of 
Healthcare for Older People, 
Royal Devon and Exeter NHS 
Foundation Trust, Exeter, UK
3NIHR Exeter Clinical Research 
Facility, University of Exeter 
Medical School, Exeter, UK
4Institute of Health Research, 
University of Exeter Medical 
School, Exeter, UK
Correspondence to
Dr W David Strain;  
 d. strain@ exeter. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objective Transient ischaemic attacks (TIA) and minor 
strokes are important risk factors for further vascular 
events. We explored the role of albumin creatinine ratio 
(ACR) in improving risk prediction after a first event.
Setting Rapid access stroke clinics in the UK.
Participants 2202 patients attending with TIA or minor 
stroke diagnosed by the attending stroke physician, able 
to provide a urine sample to evaluate ACR using a near- 
patient testing device.
Primary and secondary outcomes Primary outcome 
was major adverse cardiac events (MACE: recurrent stroke, 
myocardial infarction or cardiovascular death) at 90 days. 
The key secondary outcome was to determine whether 
urinary ACR could contribute to a risk prediction tool for 
use in a clinic setting.
Results 151 MACE occurred in 144 participants 
within 90 days. Participants with MACE had higher 
ACR than those without. A composite score awarding a 
point each for age >80 years, previous stroke/TIA and 
presence of microalbuminuria identified those at low 
risk and high risk. 90% of patients were at low risk 
(scoring 0 or 1). Their 90- day risk of MACE was 5.7%. 
Of the remaining ‘high- risk’ population (scoring 2 or 
3) 12.4% experienced MACE over 90 days (p<0.001 
compared with the low- risk population). The need 
for acute admission in the first 7 days was twofold 
elevated in the high- risk group compared with the low- 
risk group (3.23% vs 1.43%; p=0.05). These findings 
were validated in an independent historic sample.
Conclusion A risk score comprising age, previous stroke/
TIA and microalbuminuria predicts future MACE while 
identifying those at low risk of a recurrent event. This tool 
shows promise in the risk stratification of patients to avoid 
the admission of low- risk patients.
INTRODUCTION
Stroke is the second most common cause of 
death and a leading cause of disability world-
wide.1 Despite, or possibly because of, recent 
trends in reducing stroke mortality, the 
health and social disability burden of stroke 
is increasing.2 After advancing age, transient 
ischaemic attacks (TIA) and minor strokes 
are the most important risk factors for recur-
rent stroke and predict long- term mortality.3 4 
About 23% of patients presenting with stroke 
have a history of TIA in the 3 months prior 
to the index event.5 This is a key population 
to target for secondary prevention, but these 
patients represent <10% of all those who 
present to rapid access TIA clinics.6 7 Notably, 
half of all completed strokes occur within the 
first week after TIA or minor stroke.5
Accurate identification of those patients 
presenting to TIA clinics with TIA or minor 
stroke who are most at risk for future events is 
important to (1) intensify treatments such as 
giving dual antiplatelet therapy,8 9 (2) guide 
the need for urgent admission to facilitate 
the detection and urgent surgical correction 
Strengths and limitations of this study
 ► The pragmatic design of this study provides good 
generalisability to clinical practice.
 ► The predictive role of the combination of urinary 
albumin creatinine ratio (ACR) in combination with 
very basic demographics would be able to reas-
sure the 90% of the population that there was only 
approximately a 1 in 20 risk of an event recurring, 
whereas the higher risk population had a 1 in 8 
chance of a major adverse cardiac events (MACE) 
outcome.
 ► The study is limited by the availability of data which 
were available to the physicians at the time of the 
stroke appointment. This limits the ability to de-
termine mechanistic association between ACR and 
MACE outcome.
 ► Further work is required to determine whether ther-
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of severe internal carotid artery (ICA) stenosis10 and (3) 
reassure patients with lowest risk.
Several risk stratification tools are already used in such 
clinics such as ABCD211 12 (awarding points for Age, 
presenting Blood pressure, Clinical features of unilat-
eral weakness or aphasia, Duration of symptoms and 
Diabetes), California score6 and imaging- based scoring 
systems.10 13 These tools lack optimal sensitivity and spec-
ificity.12 14 Indeed some studies suggest patients with a 
‘low- risk’ ABCD2 score (<4/7) have similar 90- day stroke 
risk as patients deemed high risk with an ABCD2 score 
>4/7,15 while missing up to 40% of patients with severe 
ICA stenosis.16 As such, recent consensus guidelines have 
advised against their use.17–19
Increased urinary albumin excretion rate (AER) has 
been shown to predict incident stroke and heart failure 
in people with diabetes. In the general population, AER 
predicts cardiovascular disease and mortality post stroke 
independent of conventional cardiovascular risk factors 
such as hypertension, diabetes and smoking.20–23 Urinary 
albumin creatinine ratio (ACR) is a well- recognised proxy 
for urinary AER, and can now be assessed using simple 
and inexpensive point- of- care equipment. In an earlier 
pilot study of 142 patients with minor stroke/TIA,24 we 
identified the potential role of urinary ACR in identi-
fying those at highest risk of a recurrent event. Although 
statistically significant, this study was not large enough to 
explore potential confounding. We therefore performed 
a definitive study to assess whether urinary ACR improved 
the risk stratification of patients presenting with TIA or 
minor stroke to UK acute stroke clinics.
METHODS
Patients diagnosed with suspected minor stroke/TIA by 
a consultant stroke physician, attending a rapid access 
clinics in one of the 12 UK hospitals were recruited at 
the end of their clinic consultation. As these clinics are 
rapid access, often within the first 24 hours of symptoms, 
it was impossible to accurately differentiate between 
TIA (with symptoms <24 hours) and minor stroke in all 
cases. Only individuals with events that had occurred 
within the previous month were included in the study. 
Routine clinical care, including urgent revascularisa-
tion in those with severe ICA stenosis (>50% diameter 
stenosis by the North American Symptomatic Carotid 
Endarterectomy Trial method),25 was initiated prior to 
enrollment. If a cardioembolic source was identified, 
anticoagulants were initiated according to local proto-
cols. After written, informed consent was obtained in the 
clinic, demographics, including age, sex, height, weight, 
medical history and ABCD2 score were recorded. Times 
from onset of symptoms to assessment and enrollment in 
the study were documented. A clean specimen of urine 
was collected from participants in the clinic and tested 
with a Unistix dipstick and, if there was no indication 
of urinary tract infection (presence of any two of leuco-
cytes, nitrites and/or protein), ACR was measured using a 
point- of- care analyser (The Afinion AS100 Analyzer; Axis 
Shield, Dundee, UK). This system uses an immunometric 
membrane flow- through principle for albumin measure-
ment and an enzymatic colorimetric test for creatinine 
quantification26 and reports an ACR in approximately 
5 min within the range 0.1–140 mg/mmol with a coeffi-
cient of variation of 4.6%–6%.26 Participants with values 
of <0.1 mg/mmol were recorded as having the lowest 
recordable value of ACR (0.1 mg/mmol).
Participants were followed up by telephone on day 
7, 30 and 90, and any history of any further vascular 
events, hospitalisation or death was obtained. If contact 
with participants was not possible initially, the presence 
or absence of further events was verified during addi-
tional attempts at contact or during future follow- up. 
If no further contact was possible with the participant 
(eg, in the case of significant stroke or death), medical 
history was collected from the next of kin and verified 
from the primary care physician and hospital records. All 
reported clinical events were adjudicated according to 
the standardised diagnostic criteria by a data monitoring 
committee including two independent stroke physicians, 
blinded to the ACR, by examination of clinical records if 
they attended hospital, or their primary care physician, 
or by verifying their clinical symptoms from the research 
records if patients did not seek further medical advice. 
In the event of disagreement, a third independent stroke 
physician acted as adjudicator. The primary outcome 
was to determine the utility of microalbuminuria in 
predicting the time to first major adverse cardiovascular 
event (MACE: recurrent stroke, myocardial infarction or 
death) within 90 days. Secondary outcomes were time 
to explore the predictive role of microalbuminuria on 
recurrent stroke, total mortality (even if these were not 
the first MACE), the presence of first MACE within 7 days, 
and the need for hospitalisation within the first 7 days. All 
events were adjudicated blind to urinary ACR by an inde-
pendent data monitoring committee.
Ethics statement
The study protocol was approved by the national research 
ethics committee (approval 14/EE/1106). All participants 
provided written informed consent prior to enrolment 
and confirmed their willingness to continue participation 
at each telephone consultation.
Patient and public involvement
Patients were involved in the design and conduct of 
this research. During the feasibility stage, priority of the 
research question and methods of recruitment were 
informed by discussions with patients through a focus 
group session and three structured interviews. During the 
trial, two patients joined the independent trial steering 
committee. Once the trial has been published, partici-
pants will be informed of the results through a dedicated 
newsletter suitable for a non- specialist audience, led by 
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Statistical analysis
Data were treated as continuous variables wherever 
possible to maximise power. All normally distributed data 
are presented as mean±SD. Skewed data were appro-
priately transformed and presented as geometric mean 
scores (with 95% CIs). Statistical significance for cate-
gorical variables was calculated using the χ2 test and the 
Student’s t- test for continuous variables. Time to event 
was measured from the clinic consultation rather than 
the index event, in keeping with the pragmatic nature 
of the study. Independence of ACR (as a risk predictor) 
from diabetes and other measures of the ABCD2 score 
was assessed using logistic regression. Microalbuminuria 
was defined using the currently accepted clinical thresh-
olds for microalbuminuria used in people with diabetes 
3.5 mg/mol for women and 2.5 mg/mol for men. Iden-
tification of independent predictors of recurrent MACE 
was performed by backwards stepwise logistic regres-
sion, commencing with all information available for 
the complete dataset, representing all information that 
would routinely be available to the clinician in the clinic 
setting. Where multiple related measures were available 
(eg, systolic, diastolic and mean arterial blood pressure), 
the variable that accounted for the greatest degree of 
variance in a univariate analysis was included. Fractional 
polynomial regression modelling was used to identify 
sex- specific thresholds of ACR to define ‘microalbumin-
uria’ in the context of stroke risk stratification. Predic-
tion of events were calculated using a Cox proportional 
HR with time to first MACE as the primary outcome. In 
keeping with the recommendations of Cupples et al27 and 
Rothman,28 the measured significance of the variables 
of interest is reported without adjustment for multiple 
testing. Statistical significance was considered at p<0.05. 
Statistical analysis was performed using Stata SE V14.2 
(Mac version: StataCorp LLC, College Station, TX, USA).
RESULTS
A total of 2408 patients with a diagnosis of definite or 
probable minor stroke/TIA were recruited; 149 partic-
ipants were subsequently excluded after the diagnosis 
Table 1 Sample characteristics of total population and population stratified by occurrence of recurrent vascular events or 
death (MACE) at 90 days
Characteristic Total population No event by 90 days Event at 90 days
N 2202 2058 144
Days from event to clinic† 3 (1–6) 3 (1–6) 2 (1–4)
Age (years) 70.9 (11.7) 70.9 (11.6) 72.2 (12.2)
Sex (% male) 64.8 64.7 67.9
Height (m) 1.70 (0.10) 1.70 (0.10) 1.71 (0.9)
Weight (kg) 79.8 (17.1) 79.9 (17.0) 79.7 (17.7)
BMI (kg/m2) 27.6 (5.2) 27.6 (5.2) 27.2 (4.9)
Blood pressure
  Systolic (mm Hg) 144.1 (20.8) 144.2 (20.9) 145.7 (21.7)
  Diastolic (mm Hg) 81.8 (12.6) 81.7 (12.6) 83.8 (13.1)
Total cholesterol (n=1466) (n=1374) (n=92)
  (mmol/L)‡ 5.02 (2.57) 194 5.03 (2.63) 4.75 (1.24)
  (mg/dl)‡ 194(99) 195 (102) 183 (48)
Diabetes (%) 15.7 15.9 12.1
Previous stroke (%) 4.0 3.5 10.7*
ABCD2
  Mean score out of 7 4.0 (1.4) 4.0 (1.4) 4.1 (1.4)
  Proportion >4 (%)
  ‘High risk’
62.5 62.3 65.0
ACR (mg/mmol)§ 1.79 (0.9–2.9) 1.75 (1.69–1.83) 2.27 (1.92–2.68)**
ACR (mg/g)§ 15.8 (8.0–25.6) 15.5 (14.9–16.2) 20.1 (17.0–23.7)**
*p<0.0001 compared with those with no events; **p=0.002 compared with those with no events.
†Median (IQR).
‡These data were collected from patient records where clinician had requested the test and therefore only available in a subset of the 
population.
§Geometric mean (95% CI).
ABCD2, Age, presenting Blood pressure, Clinical features of unilateral weakness or aphasia, Duration of symptoms and Diabetes; ACR, 
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was revised to that of a stroke mimic, 8 withdrew consent 
and a further 49 (2%) were excluded due to intercurrent 
urinary tract infection rendering the assessment of ACR 
invalid. No patient was lost to follow- up. Baseline charac-
teristics are presented in table 1. Of the 2202 included in 
the final analysis, most were male (64.9%). All patients 
were commenced on secondary prevention with appro-
priate antiplatelet or anticoagulant therapy, and an 
appropriately dosed statin in accordance with contempo-
raneous national guidelines.
Over 90 days, 151 primary outcome events (MACE) 
occurred in 144 participants (6.7% of patients) including 
8 cardiovascular deaths. All MACE were atherosclerotics 
with no haemorrhagic events occurring in the 3 months. 
There were also eight non- cardiovascular deaths. Within 
7 days, there were 38 MACE in 36 participants. Those with 
MACE were more likely to have had previous stroke/TIA, 
however, with this exception, there were no significant 
differences in routinely collected clinic data (table 1). 
There was no difference in mean ABCD2 score or the 
proportion of participants with a ‘high- risk’ score (4/7 or 
more) between those who did and did not have events by 
90 days. When looking exclusively at the 1374 participants 
identified with a ‘high- risk’ ABCD2 score (63% of the 
study sample; 93% male), a high score did not distinguish 
those at high risk of MACE compared with those with an 
ABCD2 <4 (HR 1.15 (0.82–1.63); p=0.4), nor did a low 
risk score exclude an event, with only 37.7% of people 
who have not experienced MACE outcome scoring <4. 
Point- of- care ACR was higher in those participants with 
a primary outcome event at 90 days compared with those 
without (2.27 (1.92–2.68) vs 1.75 (1.68–1.83) mg/mmol, 
respectively; p=0.002). This distinction remained after 
adjustment for age and sex (adjusted ACR 2.40 (2.04–
2.83) vs 1.88 (1.80–1.96), p=0.004; figure 1).
Evaluation of the prognostic role of microalbuminuria alone
Fractional polynomial regression modelling identified 
the sex- specific threshold of risk for ACR aligned with the 
currently accepted thresholds for microalbuminuria used in 
people with diabetes of 2.5 mg/mmol for men and 3.5 mg/
mol for women. These thresholds identified 562 participants 
(25.4% of the study sample; 75% male) with microalbumin-
uria. These participants were more likely than those with a 
low ACR to experience a primary outcome event (HR 1.66 
(95% CI 1.19 to 2.34); p=0.003) and had a greater than 
fivefold increase in 90- day mortality (HR 5.44 (1.86–15.90); 
p=0.0003). Alone, however, microalbuminuria did not have 
sufficient positive or negative predictive value to justify its 
clinical utility (positive predictive value (PPV): 9.1%, speci-
ficity: 75.4%).
Generating a composite risk score for 90-day risk 
stratification
In a stepwise multivariate model, the only independent 
predictors of MACE were elevated ACR, age >80 years and 
history of stroke or TIA. Similar variance within the model 
was explained microalbuminuria (ie, an ACR >2.5 mg/
mol and 3.5 mg/mol, respectively, in men and women) as 
being older than 80 years of age and history of stroke/
TIA, so they were afforded equal weighting. This gener-
ated a 4- point scale between 0 and 3 (termed the ‘APA’ 
score representing age, prior stroke or TIA and elevated 
ACR), with the lowest risk participants having a score of 
0 (online supplemental table 1). There was a sequential 
increase in risk with increasing score such that those with 
a score of 0 having a 90- day risk of 4.86% rising to a 30% 
risk for those with the highest score (online supplemental 
table 2). The population was then divided into a low- risk 
group scoring 0 or 1 or high- risk scoring 2 or 3. A total 
of 1985 (90.1%) of participants were identified as low 
risk compared with 217 (9.9%) in the high- risk group. 
When comparing the PPV sensitivity and specificity of 
the APA score compared with the previously available 
parameters of age and previous stroke demonstrated a 
clinically meaningful improvement over each measure on 
its own (online supplemental table 3A). Compared with 
using previous stroke alone, APA score had a similar PPV 
(12.4% for APA score vs 11.9% for previous stroke) and 
specificity (91.2% vs 96.4%, respectively), however supe-
rior sensitivity (19.3% vs 7.1%, respectively). Sensitivity 
was improved using a composite of previous stroke and 
being above the age of 80 years; however, this was at the 
expense of a reduction of PPV to 8.4%.
The high- risk group was older, with higher systolic blood 
pressure and pulse pressure compared with the low- risk 
group (table 2). The 90- day risk of MACE outcome was 
5.7% in the low- risk group versus 12.4% in the high- risk 
group (p<0.001), translating to a HR of 2.12 (95% CI 1.38 
to 3.25) for the high- risk score compared with low- risk group 
(p<0.001; figure 2). This was predominantly driven by an 
increase in recurrent stroke/TIA (3.3% vs 8.8%; HR 2.67 
(1.58–4.51); p<0.001). This difference was apparent within 
Figure 1 Age and sex- adjusted albumin creatinine ratio 
(mean±95% CI) stratified by the occurrence of MACE in 
the first 90 days post initial event. MACE, major adverse 
cardiovascular events such as recurrent cerebrovascular 
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7 days of the clinic, such that those with a high APA score had 
a 2.2- fold increased risk of a recurrent event.
One thousand and forty- nine participants were reviewed 
within 48 hours of their index event. For these individuals, 
the predictive role of the APA score was numerically supe-
rior (HR 2.84, 95% CI 1.32 to 6.14; p=0.008) than those 
who were seen with a longer delay. There was no signifi-
cant interaction between time from event to appointment 
and predictive role of the APA score.
Validation of APA score on a historic sample
To validate the APA score, we applied the tool to the 
individuals who participated in the pilot study but did 
not contribute their data to this dataset. Details of this 
pilot study have been published elsewhere.24 In brief, 
the pilot study recruited 139 participants over 9 months 
from one of the centres involved in the definitive study. In 
this population, there were 13 recurrent events (9.35%) 
within the 90 days, 9 of which occurred in the first 7 days 
after attendance to the stroke clinic (table 3). The APA 
risk score replicated a similar distribution of number of 
participants at low risk (73%) and high risk (27%) as in 
the larger study. Compared with the component parts, the 
APA score had superior positive predictive value (24.4% 
vs 18.2% for previous stroke or 13.3% for previous stroke 
and being aged >80 years) and superior sensitivity (76.9% 
vs 46.2% vs 15.4%, respectively; online supplemental 
table 3B). At 90 days, 5.9% of the low APA group had 
recurrent events compared with 18.4% of the in the high 
APA group (p=0.02). Again, within the first 7 days this was 
apparent with only 1.9% of the low APA group experi-
encing the primary outcome, compared with 13.2% in 
the high APA group (p=0.04).
DISCUSSION
In this large UK multicentre prospective study with 
blinded outcome adjudication, we have demonstrated 
the utility of an elevated ACR, measured using a simple 
point- of- care analyser, in combination with simple clinical 
data (age and history of stroke or TIA) in the prediction 
of MACE and death. This differentiates between low- risk 
and high- risk individuals. Specifically, >90% of individuals 
were identified as low risk with<1.5% risk of a MACE or 
death over the next 7 days, increasing to 5.7% by 90 days, 
whereas 9.9% of the population were identified as high 
Table 2 Occurrence of events by APA risk score group (mean±SD for continuous variable, p for ANOVA; % for categorical 
data, p for χ2)
Low risk High risk P value
n 1985 217
Sex (% male) 64.5 68.2 0.2
Age (years) 69.6 (11.3) 84.0 (5.0) <0.0001
Blood pressure (mm Hg)
  Systolic 143 (20.4) 150.5 (23.3) <0.0001
  Diastolic 82 (12.3) 79 (11.6) 0.0007
Weight (kg) 80.3 (17.1) 75.1 (16.2) <0.0001
Diabetes 15.3 18.9 0.2
MACE at 90 days (%)
  All events 5.7 12.4 <0.0001
  Cerebrovascular event 3.2 8.8 <0.0001
  Cardiovascular mortality 0.1 1.4 <0.001
  All cause mortality 0.4 2.3 0.001
MACE at 7 days (%) 1.46 3.23 0.05
ACR, albumin creatinine ratio; APA, age, prior stroke or TIA and elevated ACR; MACE, major adverse cardiac events; TIA, transient ischaemic 
attacks.
Figure 2 Time to first MACE stratified by age, previous 
cerebrovascular event, high ACR risk score. Event rate 
in high- risk group (n=217) 12.44% versus low- risk group 
(n=1985) 5.69%, HR 2.12 (1.38–3.25) p<0.001. ACR, albumin 
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risk with a 12.4% event rate over 90 days. Although only 
a small number, our findings were validated in a separate 
historic population who participated in the pilot study.
The utility of APA scoring may go beyond simply 
guiding conversations regarding prognosis in a clinic 
setting. The Platelet- Oriented Inhibition in New TIA 
and Minor Ischaemic Stroke (POINT) Trial8 and (Clopi-
dogrel in High- Risk Patients with Acute Nondisabling 
Cerebrovascular Events) CHANCE trial9 demonstrated 
the benefit of dual antiplatelet therapy in the first 21 days 
after high- risk TIA. There was, however, a 0.5% absolute 
increase in major intracranial haemorrhage. We would 
propose that an assessment of the APA score could be 
evaluated as a stratification tool to determine whether it 
predicts those who benefit the most. In those with a low- 
risk APA score, even the 25% relative risk reduction in 
the POINT trial would result in only a marginally benefi-
cial risk:benefit ratio, assuming that microalbuminuria is 
a predictor of thromboembolic disease processes. Those 
with a high APA score, however, would likely benefit from 
dual antiplatelet therapy with a number need to treat of 
<30 to prevent an event. This suggestion, however, does 
require confirmation in an independent study. The APA 
score also gives additional information that is of use in 
the more acute setting. Over the first 7 days, a low- risk 
APA score had a negative predictive value of >98.5% for 
the risk of MACE—a number very similar to the predic-
tive effect of troponin when evaluating suspected cardiac 
chest pain.29
When considering the populations identified by the 
APA score, there are similarities to the ABCD2 score. 
Indeed, the demographics of the high- risk group were 
older, with higher blood pressure and a trend towards 
more diabetes. We would suggest, that microalbumin-
uria represents vascular susceptibility to the adverse 
consequences of hypertension and diabetes rather than 
simply an indication of the presence of hypertension 
and/or diabetes in general. This would explain why the 
APA score predicted further MACE and total mortality at 
7 and 90 days, whereas in our large sample the ABCD2 
score did not.
Elevated ACR is a recognised marker of gener-
alised endothelial and microvascular dysfunction. The 
increased filtration of albumin through the renal glomer-
ular filtration barrier is thought to be due to changes in 
the chemical and physical properties of this endothelial 
barrier and its glycocalyx.30–32 The mechanism explaining 
the association between microalbuminuria and incident 
cardiovascular events is thought to depend on its role as 
a marker of systemically increased vascular permeability 
and altered homeostasis, coagulation and endothelial 
function.33–38 However, after acute ischaemic events such 
as myocardial infarction, or as demonstrated here TIA or 
minor stroke, it is likely that elevated urinary ACR is, at 
least in part, dependent on the systemic inflammatory 
response to the original insult.
Although unlikely to be mechanistically involved in the 
progression of disease, the question as to whether it is a 
good surrogate of therapeutic effect remains. Improving 
systemic inflammation, such as through the pleiotropic 
effect of statins, has been associated with simultaneous 
improvements in urinary albumin excretion and cardio-
vascular event rates in patients with elevated high sensi-
tivity C reactive protein.39–41 Further studies are needed to 
determine whether microalbuminuria after acute stroke 
represents a therapeutic target amenable to treatment, 
and if reductions in microalbuminuria are associated with 
reductions in the vascular events they predict.
Limitations and strengths of this study
Recurrent event rate was lower than anticipated from 
our pilot study and contemporaneous clinical trials such 
Table 3 Occurrence of events by APA risk score group in independent validation population (mean±SD for continuous 
variable, p for ANOVA; % for categorical data, for χ2)
Low risk High risk P value
n 101 38
Sex (% male) 51.5 71.5 0.04
Age (years) 72.6 (10.7) 81.6 (6.1) 0.001
Blood pressure (mmHg)
  Systolic 142.6 (20.2) 147.3 (26.6) 0.3
  Diastolic 77.7 (9.8) 77.4 (10.8) 0.9
Weight (kg) 76.2 (16.4) 75.0 (15.4) 0.7
Recurrent event at 90 days (%)
  MACE 5.9 18.4 0.02
Recurrent event at 7 days (%)
  MACE* 1.9 13.2 0.04
*MACE include recurrent stroke or TIA, myocardial infarction or cardiovascular death.
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as CHANCE (11.7% in the control arm),9 although are 
comparable with the recently reported randomised 
controlled POINT trial (6%).8 In usual practice it is 
usually 24–48 hours between the index event and clinic 
attendance. Given that data from previous studies has 
demonstrated the highest risk occurs in the first 48 hours, 
it is likely that some events will have occurred between the 
index event and attendance in the clinic in our study.42 
The pragmatic design of the study, however, is also a 
strength given that the predictive role highlights those 
that may benefit from dual antiplatelet therapy or hospi-
talisation when the patient is seen in the acute stroke 
clinic.
There is no consensus on the gold standard for diag-
nosing TIA in a rapid access stroke clinic.43 In order to 
maintain the generalisability of the study, all attendees 
of the stroke clinic that were diagnosed with a probable 
or definite TIA were invited to participate. Only a small 
number of patients were subsequently withdrawn as being 
stroke mimics. Outcome events were rigorously adju-
dicated against published diagnostic criteria to ensure 
consistency and reliability.
Finally, the use of a single urinary ACR sample obtained 
during the clinic assessment using a near patient testing 
kit is not as robust as a sample tested in a central labo-
ratory. Although there is significant diurnal variability in 
urinary AER within individuals, potentially limiting the 
scientific or mechanistic merit of the study compared 
with studies using overnight or 24- hour urine collection, 
the pragmatic design makes this study more applicable 
to general clinic populations. Furthermore, the relatively 
low cost of the near patient test kit makes it accessible in 
most emergency settings, in primary and secondary care.
CONCLUSION
We have demonstrated for the first time the potential 
utility of a single point- of- care test of urinary ACR in 
patients presenting with TIA and minor stroke as a predic-
tion tool to assist triaging patients. When used in combi-
nation with patient age and history of stroke or TIA, this 
generated a risk stratification score (the APA score: age 
>80 years, previous stroke/TIA and elevated ACR) that 
could reliably identify the large proportion of patients 
with a low risk of recurrent vascular event over the next 90 
days. The value of ACR that is most predictive is aligned 
with the conventional definition of microalbuminuria 
used in diabetes, suggesting that in clinical practice the 
existing technology for evaluating microalbuminuria 
including urine dipsticks may be used. A high APA score 
was associated with a doubling of risk of MACE outcome 
and a fivefold increase in mortality. This APA score was 
validated in an independent population. We believe the 
APA score may represent a practical tool for clinicians 
engaged in the acute ambulatory assessment of TIA and 
minor stroke, to assist in the assessment of risk:benefit 
ratio for the use dual antiplatelet therapy or to admit 
for more urgent investigation. Further work is required 
to determine whether the increase in ACR represents a 
therapeutic target or solely a prognostic indicator.
Twitter W David Strain @DocStrain
Acknowledgements WDS is supported by the NIHR Exeter Clinical Research 
Facility. WDS and MAJ is supported by the NIHR SW Peninsula Applied Research 
Collaboration.
Contributors WDS and ACS conceived and designed the study, attained funding, 
were involved in the management of the trial. WDS produced the first draft of the 
manuscript. SE, NW and MJ contributed to the design and management of the trial. 
LM and WH provided the statistical support for the management of the trial and the 
analysis of the outcomes. All authors have reviewed the final manuscript prior to 
submission.
Funding This study was funded by a NIHR Research for Patient Benefit grant (PB- 
PG-1112-29069) and supported by the NIHR Exeter Clinical Research Facility.
Disclaimer This manuscript does not necessarily reflect the views of the NIHR, the 
Exeter Clinical Research Facility, the NHS or the UK Department of Health.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request to the 
corresponding author.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
W David Strain http:// orcid. org/ 0000- 0002- 6826- 418X
Luke Mounce http:// orcid. org/ 0000- 0002- 6089- 0661
REFERENCES
 1 Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res 
2017;120:439–48.
 2 Henssge U. National sentinel stroke clinical audit 2010. In: Royal 
College of Physicians, ed, 2011.
 3 Burn J, Dennis M, Bamford J, et al. Long- Term risk of recurrent 
stroke after a first- ever stroke. The Oxfordshire community stroke 
project. Stroke 1994;25:333–7.
 4 Hankey GJ. Long- Term outcome after ischaemic stroke/transient 
ischaemic attack. Cerebrovasc Dis 2003;16 Suppl 1:14–19.
 5 Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time 
window for prevention is very short. Neurology 2005;64:817–20.
 6 Johnston SCet al. Short- Term prognosis after emergency department 
diagnosis of TIA. JAMA 2000;284:2901–6.
 7 Hill MD, Yiannakoulias N, Jeerakathil T, et al. The high risk of stroke 
immediately after transient ischemic attack: a population- based 
study. Neurology 2004;62:2015–20.
 8 Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and 
aspirin in acute ischemic stroke and high- risk TIA. N Engl J Med 
2018;379:215–25.
 9 Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in 
acute minor stroke or transient ischemic attack. N Engl J Med 
2013;369:11–19.
 10 Kiyohara T, Kamouchi M, Kumai Y, et al. Abcd3 and ABCD3- I 




















pen: first published as 10.1136/bm






8 Strain WD, et al. BMJ Open 2021;11:e043253. doi:10.1136/bmjopen-2020-043253
Open access 
long- term risks of stroke after transient ischemic attack. Stroke 
2014;45:418–25.
 11 Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) 
to identify individuals at high early risk of stroke after transient 
ischaemic attack. The Lancet 2005;366:29–36.
 12 Bhatt A, Jani V. The ABCD and ABCD2 scores and the risk of stroke 
following a TIA: a narrative review. ISRN Neurol 2011;2011:1–12.
 13 Ay H, Arsava EM, Johnston SC. Clinical- and imaging- based 
prediction of stroke risk after transient ischemic attack: the CIP 
model. Stroke; a journal of cerebral circulation 2009;40:181–6.
 14 Giles MF, Rothwell PM. Systematic review and pooled analysis of 
published and unpublished validations of the ABCD and ABCD2 
transient ischemic attack risk scores. Stroke 2010;41:667–73.
 15 Amarenco P, Labreuche J, Lavallée PC. Patients with transient 
ischemic attack with ABCD2 <4 Can Have Similar 90- Day Stroke 
Risk as Patients With Transient Ischemic Attack With ABCD2 ≥4. 
Stroke 2012;43:863–5.
 16 Amarenco P, Labreuche J, Lavallee PC. Patients with transient 
ischemic attackwith ABCD2 <4 can have similar 90- day stroke risk 
as patients with transient ischemic attack with ABCD2 >/=4. Stroke 
2012;43:863–5.
 17 National Institute of Health and Care Excellence. Stroke and transient 
ischaemic attack in over 16s: diagnosis and initial management; NICE 
guideline [NG128]. National Institute of Health and Care Excellence, 
2019: 2019.
 18 Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the 
early management of patients with acute ischemic stroke: a guideline 
for healthcare professionals from the American heart Association/
American stroke association. Stroke 2018;49:e46–110.
 19 Ahmed N, Audebert H, Turc G, et al. Consensus statements 
and recommendations from the ESO- Karolinska stroke update 
Conference, Stockholm 11-13 November 2018. Eur Stroke J 
2019;4:307–17.
 20 Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of 
cardiovascular events, death, and heart failure in diabetic and 
nondiabetic individuals. JAMA 2001;286:421–6.
 21 Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion 
predicts cardiovascular and noncardiovascular mortality in general 
population. Circulation 2002;106:1777–82.
 22 Yuyun MF, Khaw K- T, Luben R, et al. Microalbuminuria, 
cardiovascular risk factors and cardiovascular morbidity in a 
British population: the EPIC- Norfolk population- based study. Eur J 
Cardiovasc Prev Rehabil 2004;11:207–13.
 23 Strain WD, Shore AC, Melzer D. Albumin:creatinine ratio predicts 
mortality after stroke: analysis of the Third National Health and 
Nutrition Examination Survey. J Am Geriatr Soc 2010;58:2434–5.
 24 Elyas S, Shore AC, Kingwell H, et al. Microalbuminuria could improve 
risk stratification in patients with TIA and minor stroke. Ann Clin 
Transl Neurol 2016;3:678–83.
 25 Morgenstern LB, Fox AJ, Sharpe BL, et al. The risks and benefits of 
carotid endarterectomy in patients with near occlusion of the carotid 
artery. North American symptomatic carotid endarterectomy trial 
(NASCET) group. Neurology 1997;48:911–5.
 26 Kvam C. Afinion ACR scientific poster AACC 2007. Axis- Shield POC 
as, 2007. Available: http://www. afinion. net/ publications
 27 Cupples LAet al. Multiple testing of hypotheses in comparing two 
groups. Ann Intern Med 1984;100:122–9.
 28 Rothman KJ. No adjustments are needed for multiple comparisons. 
Epidemiology 1990;1:43–6.
 29 Gualandro DM, Puelacher C, LuratiBuse G, et al. Comparison of 
high- sensitivity cardiac troponin I and T for the prediction of cardiac 
complications after non- cardiac surgery. Am Heart J 2018;203:67–73.
 30 Haraldsson B, Jeansson M. Glomerular filtration barrier. Curr Opin 
Nephrol Hypertens 2009;18:331–5.
 31 Singh A, Satchell SC. Microalbuminuria: causes and implications. 
Pediatr Nephrol 2011;26:1957–65.
 32 Gansevoort RT, Lambers H, Witte EC. Methodology of screening for 
albuminuria. Nephrology Dialysis Transplantation 2007;22:2109–11.
 33 Barzilay JI, Peterson D, Cushman M, et al. The relationship of 
cardiovascular risk factors to microalbuminuria in older adults with or 
without diabetes mellitus or hypertension: the cardiovascular health 
study. Am J Kidney Dis 2004;44:25–34.
 34 Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular 
disease mortality associated with microalbuminuria and gross 
proteinuria in persons with older- onset diabetes mellitus. Arch Intern 
Med 2000;160:1093–100.
 35 Dinneen SF, Gerstein HC. The association of microalbuminuria and 
mortality in non- insulin- dependent diabetes mellitus. A systematic 
overview of the literature. Arch Intern Med 1997;157:1413–8.
 36 Festa A, D'Agostino R, Howard G, et al. Inflammation and 
microalbuminuria in nondiabetic and type 2 diabetic subjects: 
the insulin resistance atherosclerosis study. Kidney Int 
2000;58:1703–10.
 37 Asselbergs FW, de Boer RA, Diercks GFH, et al. Vascular endothelial 
growth factor: the link between cardiovascular risk factors and 
microalbuminuria? Int J Cardiol 2004;93:211–5.
 38 Stehouwer CDA, Gall M- A, Twisk JWR, et al. Increased urinary 
albumin excretion, endothelial dysfunction, and chronic low- 
grade inflammation in type 2 diabetes: progressive, interrelated, 
and independently associated with risk of death. Diabetes 
2002;51:1157–65.
 39 Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent 
vascular events in men and women with elevated C- reactive protein. 
N Engl J Med 2008;359:2195–207.
 40 Abe M, Maruyama N, Okada K, et al. Effects of lipid- lowering therapy 
with rosuvastatin on kidney function and oxidative stress in patients 
with diabetic nephropathy. J Atheroscler Thromb 2011;18:1018–28.
 41 Girardi JM, Farias RE, Ferreira AP, et al. Rosuvastatin prevents 
proteinuria and renal inflammation in nitric oxide- deficient rats. 
Clinics 2011;66:1457–62.
 42 Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent 
stroke: evidence of the need for a standard definition. Stroke 
2004;35:1925–9.
 43 Graham C, Bailey D, Hart S, et al. Clinical diagnosis of TIA or minor 
stroke and prognosis in patients with neurological symptoms: a rapid 




















pen: first published as 10.1136/bm






Supplementary Table 1: APA (Age, Previous Stroke and ACR) Score derivation 
 Variable Value 
Age ≥80 years 1 
Previous stroke or TIA Present 1 
ACR  
≥3.5 mg/mmol for women 
≥2.5 mg/mol for men 
1 
   
 
 
Score 0-1 2-3 
Risk Low Risk High Risk 
 
ACR: Albumin Creatinine Ratio 
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Supplementary Table 2: Occurrence of major adverse cardiac events (MACE) by APA risk 
score group (p for Chi-Squared) 
 
APA score N 
Occurrence of MACE 
events (%) 
0 1215 4.9 
1 770 7.0 
2 207 11.6 
3 10 30 
  P<0.001 
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Supplementary Table 3 
The predictive values of the elements of the APA score compared to the total score in the study and the validation population. 
 
Table 3a The predictive values in the original study population 
 
 PPV NPV Sensitivity Specificity 
Aged >80 years 7.9% 94.2% 32.1% 74.7% 
Previous Stroke 11.9% 93.9% 7.1% 96.4% 
Age >80 years and Previous Stroke 8.4% 94.5% 37.9% 72.1% 
APA score ≥2 12.4% 94.6% 19.3% 91.2% 
 
Table 3b The predictive values in the validation population 
 
 PPV NPV Sensitivity Specificity 
Aged >80 years 9.8% 91.3% 38.5% 64.6% 
Previous Stroke 18.2% 93.6% 46.2% 79.2% 
Age >80 years and Previous Stroke 13.3% 91.4% 15.4% 90.0% 
APA score ≥2 24.4% 96.9% 76.9% 75.4% 
 
PPV Positive Predictive Value 
NPV  Negative Predictive Value 
APA Composite of Age >80 years, Previous stroke, elevated ACR. A score of 2 or 3 are regarded as high risk 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-043253:e043253. 11 2021;BMJ Open, et al. Strain WD
